COMPANY

Arisan Therapeutics, Inc.

HQ: Carlsbad, CA source · arisanthera.com ↗ · West Coast

Also known as Arisan Therapeutics · 32 sources

Arisan Therapeutics is a clinical-stage biotechnology company advancing government-funded infectious disease programs for Ebola and Lassa fever while exploring applications of its small-molecule platform in metabolic disease. From company website Source · Oct 12, 2026

Keywords: infectious disease small molecule influenza virus infection Pharmacokinetics After Oral Intake infectious diseases ARN-75039

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)25NIH grants

Funding and NIH signals

NIH award NIH awarded $1M (SBIR commercialization 5SB1AI112097-10, continuation, notice May 22, 2026). NIH RePORTER 5SB1AI112097-10 (May 22, 2026)
Evidence (1 event)
- May 22, 2026 · NIH RePORTER 5SB1AI112097-10
  Organization: ARISAN THERAPEUTICS, INC.; City/State: Carlsbad, CA; Project number: 5SB1AI112097-10; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-05-22; FY total cost (award amount): 1000000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 3, 2026 Grant Government grant — NIH N01: $2.93M (annual award, as published), announced Aug 3, 2026. Agency: NIH/OD. Source: government award database. source ↗
May 22, 2026 Grant Government grant — SBIR: $1M (annual award, as published), announced May 22, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 14, 2026 Trial start Phase 2: ARN-75039 Lassa Fever Treatment in West Africa source ↗
May 21, 2025 Grant Government grant — NIH R01: $915,066 (annual award, as published), announced May 21, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 27, 2025 Trial start Phase 1: A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed source ↗
Feb 12, 2025 Grant Government grant — SBIR: $1M (annual award, as published), announced Feb 12, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jan 23, 2023 Trial start Phase 1: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects source ↗

Funding

Last 2 years.

Aug 3, 2026 Government grant — NIH N01: $2.93M (annual award, as published), announced Aug 3, 2026. Agency: NIH/OD. Source: government award database. source ↗
May 22, 2026 Government grant — SBIR: $1M (annual award, as published), announced May 22, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
May 21, 2025 Government grant — NIH R01: $915,066 (annual award, as published), announced May 21, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 12, 2025 Government grant — SBIR: $1M (annual award, as published), announced Feb 12, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT07419373	ARN-75039 Lassa Fever Treatment in West Africa	Phase 2	Suspended	Feb 14, 2026	2027-06 (estimated)
NCT06911242	A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions	Phase 1	Completed	Feb 27, 2025	Apr 21, 2025 (actual)
NCT05735249	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects	Phase 1	Completed	Jan 23, 2023	Mar 28, 2025 (actual)

NIH awards 25

Annual award amounts. Total $20.7M.

Apr 23, 2024 NIH award 5R01AI160246-04 FY2024: $1,065,105 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. IND-Enabling Studies for source ↗
Mar 11, 2024 NIH award 2SB1AI112097-08A1 FY2024: $1,000,000 awarded for that fiscal year; activity SB1 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Initiation of ARN-75039 API source ↗
Jun 13, 2023 NIH award 5R01AI160246-03 FY2023: $1,085,888 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. IND-Enabling Studies for source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93023C00051-0-9999-1 FY2023: $3,692,037 awarded for that fiscal year; activity N01 (OTHER_NIH); PI HENKEL, GREG; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. DEVEL source ↗
Apr 22, 2022 NIH award 5R01AI160246-02 FY2022: $1,085,584 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. IND-Enabling Studies for source ↗
Feb 18, 2022 NIH award 5R44AI112097-07 FY2022: $997,332 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Pre-IND Development of an Arena source ↗
May 13, 2021 NIH award 1R01AI160246-01 FY2021: $1,308,008 awarded for that fiscal year; activity R01 (OTHER_NIH); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. IND-Enabling Studies for source ↗
Feb 22, 2021 NIH award 5R44AI112097-06 FY2021: $999,816 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Pre-IND Development of an Arena source ↗
Apr 9, 2020 NIH award 5R44AI127055-03 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Development of a Highly Sensi source ↗
Mar 2, 2020 NIH award 2R44AI112097-05 FY2020: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Pre-IND Development of an Are source ↗
Apr 29, 2019 NIH award 2R44AI127055-02A1 FY2019: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Development of a Highly Sen source ↗
Mar 4, 2019 NIH award 5R43AI138878-02 FY2019: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI MCCORMACK, KEN J; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Optimization of Ebola Virus Entry Inhi source ↗
Feb 12, 2018 NIH award 1R43AI138878-01 FY2018: $350,000 awarded for that fiscal year; activity R43 (SBIR); PI MCCORMACK, KEN J; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Optimization of Ebola Virus Entry Inhi source ↗
Mar 2, 2017 NIH award 5R44AI112097-04 FY2017: $1,500,000 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Arenavirus Antiviral Lead Opt source ↗
Jul 18, 2016 NIH award 1R41AI127055-01 FY2016: $300,000 awarded for that fiscal year; activity R41 (STTR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Ultrasensitive Point-of-Care Di source ↗
Mar 28, 2016 NIH award 2R44AI112097-03 FY2016: $1,500,000 awarded for that fiscal year; activity R44 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Arenavirus Antiviral Lead Opt source ↗
Jan 28, 2015 NIH award 1R43AI118207-01 FY2015: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI MCCORMACK, KEN J; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Ebola Virus Entry Inhibitors source ↗
Jan 15, 2015 NIH award 5R43AI112097-02 FY2015: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI PLEWE, MICHAEL BRUNO; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Optimization of Arenavirus Antivir source ↗
Aug 15, 2014 NIH award 1R43AI104106-01 FY2014: $449,400 awarded for that fiscal year; activity R43 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Identification of novel broad-s source ↗
Feb 6, 2014 NIH award 1R43AI112097-01 FY2014: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI PLEWE, MICHAEL BRUNO; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Optimization of Arenavirus Antivir source ↗
Jun 5, 2013 NIH award 1R43AI106266-01A1 FY2013: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI MCCORMACK, KEN J; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. OPTIMIZATION OF NOVEL INFLUENZA M2 C source ↗
Feb 17, 2012 NIH award 5R43AI096830-02 FY2012: $233,415 awarded for that fiscal year; activity R43 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Identification of novel influen source ↗
Dec 12, 2011 NIH award 5R43AI093035-02 FY2012: $222,059 awarded for that fiscal year; activity R43 (SBIR); PI MCCORMACK, KEN J; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Development of novel broad-spectrum in source ↗
Jul 14, 2011 NIH award 1R43AI096830-01 FY2011: $235,183 awarded for that fiscal year; activity R43 (SBIR); PI HENKEL, GREGORY WILLIAM; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Identification of novel influen source ↗
Feb 24, 2011 NIH award 1R43AI093035-01A1 FY2011: $223,202 awarded for that fiscal year; activity R43 (SBIR); PI MCCORMACK, KEN J; recipient as written: ARISAN THERAPEUTICS, INC., Carlsbad, CA. Development of novel broad-spectrum source ↗